STAT3 can be a therapeutic target for chronic active EBV infection, a fatal disorder
Credit: Department of Laboratory Molecular Genetics of Hematology,TMDU Tokyo Medical and Dental University(TMDU) study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival an..









